Search Results

You searched for : Nintedanib

	Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg According to IQVIATM sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales ... Jun 25
	New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1 New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1... Nov 07
	Cipla launches Nintib to treat Idiopathic Pulmonary Fibrosis, in continuation of its fight against rare lung diseases Cipla Limited today announced that it has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis ... Oct 21
	Glenmark introduces a generic version of NINDANIB for the treatment of Pulmonary Fibrosis Glenmark being a leader in the area of respiratory has been amongst the first to launch the branded generic version for the treatment of Pulmonary ... Oct 14
	Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (... Mar 03
	INBUILDÂ® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1 New data showed positive effect of nintedanib on slowing decline of lung function in a broad range of fibrosing interstitial lung diseases with a progressive ... Oct 01
6 Matching result(s) found!

-Advertisements-

Trending Now
	India's Commitment to Women's, Children's, and Adolescent's Health Highlighted at World Health AssemblyJune 01, 2024
	Sleep Your Way to a More Connected Life: The Role of Sleep in Combating LonelinessJune 01, 2024
	Moscow Outpatient Departments to Implement AI X-ray InterpretationMay 31, 2024
	FLO launched Digital Ready Reckoner - of MSME schemes.May 31, 2024
	Candy flavoured traps to hook the next generationMay 31, 2024
	Software Engineering Research Centre (SERC) at IIIT H to host 21st Edition of IEEE International Conference on Software Architecture (ICSA) 2024May 31, 2024
	Federal Bank and Tata AIA Life Insurance Announce Strategic Bancassurance PartnershipMay 31, 2024
	Why Whole Spices are Better than Powdered: New ICMR GuidelinesMay 31, 2024
	Raising Awareness on Menstrual Health: NCW and SheWings Initiative on Menstrual Hygiene DayMay 31, 2024
	Innovative RNA Drugs Offer Hope for Patients with High CholesterolMay 31, 2024
	Advani Hotels & Resorts (India) Limited (Caravela Beach Resort, Goa)May 30, 2024
	FLO Hyderabad launches ‘Centre of Excellence for Training Women Vegetable Farming’May 30, 2024
	Should Doctors Be Exempt from the Consumer Protection Act? A Complex DebateMay 30, 2024
	Tamil Nadu Doctors Save 14-Year-Old Girl by Removing Needle from Lung with BronchoscopyMay 30, 2024
	The Lifesaving Journey of a Florist: Rare 'Bombay' Blood Group Donation Saves Life May 30, 2024
	The Impact of Heat on Eye Health: Preventing Eye Strokes During High TemperaturesMay 30, 2024
	Patients with super morbid obesity can find life-changing benefits beyond weight reduction through bariatric surgeryMay 29, 2024
	AI software could revolutionise voice box cancer treatmentMay 29, 2024
	Why You’re Waking Up to Pee: The Link Between Enlarged Prostate and NocturiaMay 29, 2024
	Rising Smoking Rates Among Teenage Girls: A Growing Health Crisis in IndiaMay 29, 2024

Search Results

Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg

New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1

Cipla launches Nintib to treat Idiopathic Pulmonary Fibrosis, in continuation of its fight against rare lung diseases

Glenmark introduces a generic version of NINDANIB for the treatment of Pulmonary Fibrosis

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

INBUILDÂ® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1

Trending Now